These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34979059)

  • 1. Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia.
    Wang X; Raoufinia A; Bihorel S; Passarell J; Mallikaarjun S; Phillips L
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):150-164. PubMed ID: 34979059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
    Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
    Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
    Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
    Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
    Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
    Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
    Kubo M; Koue T; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males.
    Koue T; Kubo M; Funaki T; Fukuda T; Azuma J; Takaai M; Kayano Y; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2154-8. PubMed ID: 17978491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
    Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ
    J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
    Shirley M; Perry CM
    Drugs; 2014 Jul; 74(10):1097-110. PubMed ID: 24969315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
    Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
    Molden E; Lunde H; Lunder N; Refsum H
    Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.